SC
CTSO icon

Skylands Capital’s Cytosorbents Corp CTSO Stock Holding History

Skylands Capital’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$967K Sell
1,707,498
-147,017
-8% -$100K 0.13% 107
2025
Q4 		$1.19M Sell
1,854,515
-272,750
-13% -$210K 0.16% 94
2025
Q3 		$1.99M Sell
2,127,265
-489,450
-19% -$482K 0.27% 78
2025
Q2 		$3.35M Sell
2,616,715
-385,987
-13% -$388K 0.49% 57
2025
Q1 		$3M Buy
3,002,702
+221,080
+8% +$233K 0.43% 62
2024
Q4 		$2.53M Buy
2,781,622
+26,195
+1% +$25.7K 0.35% 69
2024
Q3 		$4.13M Sell
2,755,427
-85,351
-3% -$93.6K 0.56% 54
2024
Q2 		$2M Sell
2,840,778
-34,774
-1% -$30.2K 0.28% 79
2024
Q1 		$2.73M Sell
2,875,552
-378,661
-12% -$369K 0.38% 68
2023
Q4 		$3.61M Buy
3,254,213
+309,543
+11% +$460K 0.53% 53
2023
Q3 		$5.54M Buy
2,944,670
+151,200
+5% +$434K 0.84% 34
2023
Q2 		$10M Buy
2,793,470
+38,500
+1% +$122K 1.44% 16
2023
Q1 		$9.28M Buy
2,754,970
+212,879
+8% +$639K 1.36% 19
2022
Q4 		$3.94M Buy
2,542,091
+195,057
+8% +$289K 0.62% 42
2022
Q3 		$3.19M Buy
2,347,034
+22,037
+0.9% +$43K 0.52% 45
2022
Q2 		$5.09M Buy
2,324,997
+197,045
+9% +$452K 0.75% 36
2022
Q1 		$6.79M Buy
2,127,952
+181,578
+9% +$650K 0.82% 35
2021
Q4 		$8.15M Buy
1,946,374
+108,833
+6% +$611K 0.94% 32
2021
Q3 		$14.9M Buy
1,837,541
+65,541
+4% +$532K 1.84% 11
2021
Q2 		$13.4M Buy
1,772,000
+194,800
+12% +$1.64M 1.58% 16
2021
Q1 		$13.7M Buy
1,577,200
+49,800
+3% +$475K 1.74% 14
2020
Q4 		$12.2M Buy
1,527,400
+105,700
+7% +$885K 1.77% 17
2020
Q3 		$11.3M Buy
1,421,700
+228,900
+19% +$2.07M 1.89% 13
2020
Q2 		$11.8M Buy
1,192,800
+66,500
+6% +$611K 2.09% 10
2020
Q1 		$8.71M Buy
1,126,300
+310,431
+38% +$1.57M 1.93% 12
2019
Q4 		$3.14M Buy
815,869
+41,619
+5% +$182K 0.46% 52
2019
Q3 		$3.89M Buy
774,250
+93,650
+14% +$545K 0.57% 47
2019
Q2 		$4.5M Buy
680,600
+44,550
+7% +$306K 0.62% 45
2019
Q1 		$4.82M Buy
636,050
+140,200
+28% +$1.09M 0.67% 37
2018
Q4 		$4.01M Buy
495,850
+37,800
+8% +$375K 0.66% 38
2018
Q3 		$5.91M Sell
458,050
-38,500
-8% -$483K 0.76% 30
2018
Q2 		$5.66M Sell
496,550
-190,400
-28% -$1.8M 0.75% 32
2018
Q1 		$4.84M Sell
686,950
-38,658
-5% -$292K 0.64% 39
2017
Q4 		$4.72M Buy
725,608
+225,558
+45% +$1.43M 0.61% 43
2017
Q3 		$3.1M Sell
500,050
-94,200
-16% -$480K 0.41% 58
2017
Q2 		$2.56M Buy
594,250
+277,650
+88% +$1.22M 0.35% 70
2017
Q1 		$1.43M Buy
316,600
+293,600
+1,277% +$1.64M 0.2% 100
2016
Q4 		$125K Hold
23,000
– – 0.02% 165
2016
Q3 		$147K Sell
23,000
-25,350
-52% -$132K 0.02% 163
2016
Q2 		$220K Sell
48,350
-4,150
-8% -$18.1K 0.04% 160
2016
Q1 		$206K Hold
52,500
– – 0.03% 164
2015
Q4 		$292K Hold
52,500
– – 0.04% 167
2015
Q3 		$331K Buy
+52,500
New +$350K 0.04% 174

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM

Skylands Capital's CTSO Position: Q1 2026 in Review

Skylands Capital reduced its Cytosorbents Corp (CTSO) stake by 7.9% in Q1 2026, selling an estimated $100K and leaving 1,707,498 shares worth $967K. The position accounts for 0.13% of the portfolio, ranked #107.

Skylands Capital first reported a position in CTSO in Q3 2015 and has held it in 43 quarters since. The position peaked at $14.9M in Q3 2021. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • Skylands Capital held 1,707,498 shares of Cytosorbents Corp worth $967K as of Q1 2026.
  • Skylands Capital sold 147,017 Cytosorbents Corp shares in Q1 2026, an estimated $100K.
  • Cytosorbents Corp made up 0.13% of Skylands Capital's portfolio in Q1 2026, its #107 holding.
  • Skylands Capital first reported a position in Cytosorbents Corp in Q3 2015 and has held it in 43 quarters since.
  • Skylands Capital's Cytosorbents Corp position peaked at $14.9M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on Skylands Capital's 13F filing for Q1 2026, filed 22 Apr 2026.